PharmaEssentia (TPE:6446) submitted supplementary materials to the Taiwan Food and Drug Administration for its Phase I clinical trial of a TCR-T cell therapy for advanced solid tumors.
The drug, dubbed TCRT-ESO-A2-TW, is being developed in collaboration with Axis Therapeutics, according to a Thursday Taiwan Exchange filing.
The pharmaceutical company holds first negotiation rights for licensing the therapy, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.